Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 37, 2009, Pages 15879-15884

  Ziegler, C G ^a   Brown, J W ^b   Schally, A V ^b   Erler, A ^a   Gebauer, L ^a   Treszl, A ^b   Young, L ^b   Fishman, L M ^b   Engel, J B ^b   Willenberg, H S ^c   Petersenn, S ^d   Eisenhofer, G ^a   Ehrhart Bornstein, M ^a   Bornstein, S R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Aberrant receptors; Cytotoxic peptide derivatives; Targeted therapy; Tumor endocrinology

Indexed keywords

AN 162; CETRORELIX; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; GONADORELIN RECEPTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MESSENGER RNA; MZ 471; NERVE GROWTH FACTOR; NEUROPEPTIDE HORMONE RECEPTOR; NEUROPEPTIDE RECEPTOR; PEPTIDE DERIVATIVE; PROTEIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; VAPREOTIDE;

ADRENAL CORTEX TUMOR; ADRENAL GLAND; ADRENAL TUMOR; ADRENOMEDULLARY TUMOR; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROENDOCRINE TUMOR; PHEOCHROMOCYTOMA; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TUMOR CELL; TUMOR VOLUME;

2-HYDROXYPHENETHYLAMINE; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ANILINE COMPOUNDS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSTATIC AGENTS; DOXORUBICIN; GENE EXPRESSION; HUMANS; NEUROPEPTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PC12 CELLS; PYRROLES; RATS; RECEPTORS, LHRH; RECEPTORS, NEUROPEPTIDE; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN;

EID: 70349466831     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907843106     Document Type: Article

References (42)

1. Lacroix A, Ndiaye N, Tremblay J, Hamet P (2001) Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 22:75-110. (Pubitemid 32187804)
2. Mazzuco TL, Chabre O, Feige JJ, Thomas M (2007) Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol Cell Endocrinol 265-266:23-28. (Pubitemid 46273976)
3. Willenberg HS, et al. (2005) Corticotropin-releasing hormone receptor expression on normal and tumorous human adrenocortical cells. Neuroendocrinology 82:274-281. (Pubitemid 43800874)
4. Willenberg HS, et al. (1998) Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome. N Engl J Med 339:27-31.
5. Lampron A, et al. (2009) Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 94:750-756.
6. Ueberberg B, et al. (2008) Differential expression of ghrelin and its receptor (GHS-R1a) in various adrenal tumors and normal adrenal gland. Horm Metab Res 40:181-188. (Pubitemid 351690521)
7. Cartier D, et al. (2005) Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur J Endocrinol 153:939-947. (Pubitemid 43020246)
8. Bornstein SR, Stratakis CA, Chrousos GP (1999) Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 130:759-771.
9. Wolf A, et al. (2005) Adrenal pheochromocytoma with contralateral cortisol-producing adrenal adenoma: diagnostic and therapeutic management. Horm Metab Res 37:391-395. (Pubitemid 41008775)
10. Bornstein SR, Wirth MP, Schally AV (2008) Update on endocrine-related tumors. Horm Metab Res 40:299-301.
11. Abou-Jawde R, Choueiri T, Alemany C, Mekhail T (2003) An overview of targeted treatments in cancer. Clin Ther 25:2121-2137.
12. Buchholz S, et al. (2006) Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 103:10403-10407. (Pubitemid 44051179)
13. Schally AV, et al. (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248-291.
14. Plonowski A, et al. (2000) In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer 88:652-657. (Pubitemid 30805083)
15. Sun B, Schally AV, Halmos G (2000) The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 90:77-84. (Pubitemid 30331013)
16. Unger N, et al. (2008) Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf) 68:850-857. (Pubitemid 351703940)
17. Barkan AL (1998) New options for diagnosing and treating acromegaly. Cleve Clin J Med 65:347-349.
18. Drange MR, Melmed S (1998) Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab 83:3104-3109.
19. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:33-43.
20. Schally AV (2008) New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 40:315-322.
21. Nagy A, et al. (1998) Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 95:1794-1799. (Pubitemid 28103473)
22. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86-93. (Pubitemid 43355842)
23. Brouwers FM, et al. (2006) Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 1073:541-556. (Pubitemid 44912049)
24. Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566. (Pubitemid 30707306)
25. Buchsbaum DJ, Chaudhuri TR, Zinn KR (2005) Radiotargeted gene therapy. J Nucl Med 46:179-186.
26. van Essen M, et al. (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. Jun 2. [Epub ahead of print].
27. Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47.
28. Schally AV, Nagy A (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141:1-14.
29. van der Harst E, et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693.
30. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J (2008) Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52:334-340.
31. Pasquali D, et al. (2008) Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 40:263-271. (Pubitemid 351865034)
32. Pages P, et al. (1999) sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 274:15186-15193. (Pubitemid 129518858)
33. Cardoso CC, Bornstein SR, Hornsby PJ (2009) New methods for investigating experimental human adrenal tumorigenesis. Mol Cell Endocrinol 300:175-179.
34. Emons G, Ortmann O, Schulz KD, Schally AV (1997) Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 8:355-362. (Pubitemid 28034420)
35. Stangelberger A, et al. (2007) The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate 67:1339-1353. (Pubitemid 47435782)
36. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A (2000) Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85:3882-3891. (Pubitemid 30828605)
37. Koppan M, et al. (1998) Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 58:4132-4137. (Pubitemid 28440570)
38. Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300-310.
39. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781-793.
40. Merke DP, et al. (2000) Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343:1362-1368.
41. Marx C, Wolkersdorfer GW, Brown JW, Scherbaum WA, Bornstein SR (1996) MHC class II expression-a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 81:4488-4491. (Pubitemid 26412067)
42. Marx C, et al. (2003) Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosteronesulfate, and cortisol. Crit Care Med 31:1382-1388. (Pubitemid 36583847)